[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537797":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":40,"responsibleParty":57,"collaborators":26,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":26,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":26,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":26,"overallStatus":43,"whyStopped":26,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Zhongshan People's Hospital, Guangdong, China","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Study Group","EXPERIMENTAL","optimised neck CTV delineation",[13],"Radiation: Optimised neck CTV",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Group","ACTIVE_COMPARATOR","standard neck CTV delineation",[19],"Radiation: standard neck CTV",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"RADIATION","Optimised neck CTV","neck CTV delineation extends from the lateral process of C1",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"standard neck CTV","neck CTV delineation extends from skull base",[15],[32],{"name":33,"affiliation":5,"role":34},"Gui-qiong Xu, MD","PRINCIPAL_INVESTIGATOR",[36],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","+8613528109888","donna_shee@163.com",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Zhongshan City People's Hospital","RECRUITING","Zhongshan","Guangdong","528403","China","CN",{"type":50,"coordinates":51},"Point",[52,53],113.37912,22.52306,{"lat":53,"lon":52},[56],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},{"type":34,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Gui-Qiong Xu","Chief Physician","100537797","xerostomia-optimised-imrt-versus-standard-imrt-in-npc-100537797",false,"NCT06282497","Xerostomia-optimised IMRT Versus Standard IMRT in NPC","Xerostomia-optimised Intensity-modulated Radiotherapy Versus Standard Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma Patients:a Multicenter Non-inferior Randomized Controlled Phase III Clinical Trial","Inclusion Criteria:\n\n* Newly histologic diagnosis of nasopharyngeal non-keratinizing carcinoma (WHO II\u002FIII);\n* All genders, range from 18-70 years old;\n* ECOG score 0-1;\n* Clinical stage I-IVa (AJCC\u002FUICC 8th);\n* Not received radiotherapy, chemotherapy and other anti-tumor treatment (including immunotherapy);\n* No contraindications to chemotherapy or radiotherapy;\n* Adequate organ function: white blood cell count ≥ 4×109\u002FL, neutrophile granulocyte count ≥ 1.5×109\u002FL, hemoglobin ≥ 90g\u002FL, platelet count ≥ 100×109\u002FL; alanine aminotransferase or aspartate aminotransferase \\\u003C 2.5×upper limit of normal; blood urea nitrogen or creatinine ≤ 1.5×upper limit of normal or endogenous creatinine clearance ≥ 60ml\u002Fmin (Cockcroft-Gault formula);\n* Sign the consent form.\n\nExclusion Criteria:\n\n* Level II involvement with extracapsular extension (ECE), and\u002For had a maximum nodal axial diameter (MAD) of greater than 3cm in level II ;\n\n  -≥4 nodal regions of ipsilateral neck involvement;\n* Radiologically suspicious or confirmed involvement in level II area between skull base and the lateral process of C1;\n* Parotid lymph node and\u002For parotid gland involvement;\n* History of parotid disease or surgery;\n* Previous malignancy or other concomitant malignant disease;\n* Pregnancy or lactation.","ALL","18 Years","70 Years",{"count":71,"type":72},524,"ESTIMATED","INTERVENTIONAL",[75],"NA","This is a multi-center, non-inferiority, open-label, randomized controlled phase III clinical trial in primary diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis. This study aims to compare the regional control, survival outcomes, radiation-related toxicities, and quality of life (QoL) of xerostomia-optimized intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in NPC patients",[78],"Nasopharyngeal Carcinoma ,Xerostomia,Radiotherapy","2024-04-28",{"date":81,"type":82},"2024-05-01","ACTUAL",{"date":84,"type":82},"2023-10-23",{"date":86,"type":72},"2029-10-23",{"name":5,"class":6},1]